Skip to content
COVID-19 Rapid Antigen and Antibody Tests - Saliva, Nasal and Nasopharyngeal
COVID-19 Rapid Antigen and Antibody Tests - Saliva, Nasal and Nasopharyngeal

GloResponse NF-kappa-B-RE-luc2P HEK293 Cell Line

by Promega

The GloResponse Luciferase Reporter Cell Lines contain optimized, state-of-the-art luciferase reporter technology integrated into a cell line. This allows the rapid development of a reporter assay based on the pathway of interest regulating the luciferase gene. Assays configured using the GloResponse Cell Lines are amenable for high-throughput screening. These assays typically have greater response dynamics (fold of induction) than other assay formats and good quality as indicated by the high Z' values. GloResponse Cell Lines were developed to study a variety of signaling pathways. Activators of these pathways may be native to the HEK293 cell line. Activity of non-native activators can be studied after they have been introduced by transfection. The GloResponse Cell Lines were generated by clonal selection of HEK293 cells stably transfected with pGL4-based vectors carrying specific response elements for the pathway of interest. These cell lines incorporate the improvements developed for the pGL4 family of reporter vectors for enhanced performance. The destabilized luc2P luciferase reporter is used for improved responsiveness to transcriptional dynamics. The luc2P gene is codon optimized for enhanced expression in mammalian cells, and the pGL4 plasmid backbone was engineered to reduce background reporter expression. The result is a cell line with very high induction levels when the pathway of interest is activated.